Foghorn Therapeutics (FHTX) Stock Plunges 49% as Eli Lilly Terminates Partnership

Key Takeaways

Table of Contents

Shares of Foghorn Therapeutics plummeted 49% to $1.84 following Eli Lilly’s decision to terminate their collaborative cancer drug partnership.
Both companies opted against moving FHD-909 forward into expanded clinical trials after Phase 1 data proved underwhelming.
An additional joint program focused on SMARCA2 degradation is being terminated alongside the primary collaboration.
The biotech firm plans to eliminate approximately 40% of its employees as part of restructuring efforts.
Management projects the company’s available capital will last through late 2029 following the workforce reduction.

Shares of Foghorn Therapeutics experienced a devastating decline Thursday following the biotech’s announcement that its collaboration with pharmaceutical giant Eli Lilly had been discontinued. The stock plummeted 49% to $1.84 after trading resumed, representing the company’s steepest single-session decline in its history.

Foghorn Therapeutics Inc., FHTX

Shares were temporarily halted pending the disclosure. Upon resumption, a wave of selling pressure hit the stock.

The biotech firm’s market capitalization now stands at approximately $212 million. This represents a dramatic decline for a company that had secured a partnership with one of the industry’s leading pharmaceutical corporations.

The companies mutually determined that advancing FHD-909 into subsequent development stages would not proceed. The experimental therapy had recently completed its Phase 1 dose escalation study.

FHD-909 was engineered as an oral small molecule targeting the SMARCA2 protein. The therapeutic approach utilized synthetic lethality principles, specifically designed to exploit certain genetic vulnerabilities present in tumor cells.

Reasons Behind the Program Termination

CEO Adrian Gottschalk noted that the compound successfully engaged its intended molecular target. The safety profile also appeared acceptable, even when administered at doses exceeding those predicted necessary based on preclinical research.

The critical shortcoming was clinical efficacy. According to Gottschalk, the underlying biological mechanism involving the SMARCA2/4 interaction failed to produce therapeutic benefits robust enough to justify continued investment in the program.

This represents a significant setback following extensive development efforts. The implications extend beyond just the single discontinued program.

Both organizations confirmed that an additional collaborative initiative, the Selective SMARCA2 degrader program, would also be discontinued. Foghorn indicated it does not anticipate future collaborative ventures with Lilly.

The original partnership agreement was established in December 2021. Lilly’s Loxo Oncology division initiated the collaboration with $300 million in upfront payments combined with an $80 million equity investment priced at $20 per share.

Those financial terms appeared highly favorable for Foghorn when negotiated. The current trading price represents a dramatic discount from that initial $20 valuation.

Foghorn’s Path Forward

Following the partnership dissolution, Foghorn has initiated significant cost-reduction measures. The organization plans to reduce headcount by nearly 40% while implementing operational restructuring.

Leadership estimates these strategic adjustments will preserve sufficient capital to sustain operations into late 2029. This financial cushion provides runway for advancing remaining pipeline assets.

Foghorn announced its intention to concentrate resources on wholly-owned programs moving forward. This portfolio encompasses a Selective EP300 degrader, a Selective CBP degrader, and an oral candidate targeting immunology and inflammatory conditions.

The organization will maintain its induced proximity technology platform as a strategic priority. These initiatives can proceed independently without Lilly’s financial support.

Eli Lilly’s stock experienced minimal impact from the announcement. Shares declined roughly 2%, a negligible movement for a pharmaceutical company of its magnitude.

For Foghorn, the consequences are substantially more severe. The biotech must now advance independently, depending on existing capital reserves and a significantly reduced workforce to sustain its development programs through the coming years.

✨ Limited Time Offer